References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailA risk assessment tool (OSTEORISK) for identifying latin american women with osteoporosis
Sen, S. S.; Geling, O.; Messina, O. D. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 26-27

Detailed reference viewed: 36 (0 ULiège)
Full Text
Peer Reviewed
See detailEfficacy of D-Hormones in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate
Richy, Florent; Reginster, Jean-Yves ULiege

in Osteoporosis International (2002, November), 13(Suppl.3), 21

Detailed reference viewed: 3 (0 ULiège)
Full Text
Peer Reviewed
See detailType II collagen derived fragment (COLL2-1) is new marker predictive of osteoarthritis progression
Henrotin, Yves ULiege; Deberg, M.; Christgau, S. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 17

Detailed reference viewed: 24 (2 ULiège)
Full Text
Peer Reviewed
See detailOnce-weekly alendronate produces a greater decrease in bone resorption than daily risedronate
Adami, Silvio; Felsenberg, D.; Hosking, D. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 14-15

Detailed reference viewed: 12 (0 ULiège)
Full Text
Peer Reviewed
See detailTraitement hormonal de la menopause: traitement hormonal substitutif classique ou tibolone?
Reginster, Jean-Yves ULiege

in Journal de Gynécologie, Obstétrique et Biologie de la Reproduction (2002), 31(6), 541-9

OBJECTIVE: Our purpose was to review with critical analysis, data from randomized controlled clinical trials comparing the effects on bone of conventional hormone replacement therapy (HRT) and tibolone ... [more ▼]

OBJECTIVE: Our purpose was to review with critical analysis, data from randomized controlled clinical trials comparing the effects on bone of conventional hormone replacement therapy (HRT) and tibolone. Their respective effects on bone were also reviewed and summarized. Materials and methods. Medline via PubMed was searched using a combination of the following key words "tibolone, estrogens and bone" to identify all randomized controlled trials tibolone versus HRT (1960-2001). RESULTS: Six randomized controlled trials that have been carried out to compare effects of tibolone and conventional HRT on prevention of postmenopausal bone loss were identified. Only one of these trials has been performed with a correct methodology (double-blind and with an adequate duration). In this trial over 2 years, the highest significant increase from baseline in bone mineral density (BMD) at all sites was observed with HRT; in addition, HRT showed a significantly greater increase in BMD at lumbar spine than tibolone. Randomized placebo-controlled trials have demonstrated that tibolone produces positive effects on BMD. Nevertheless, no clinical convincing data are available to support its efficacy in the prevention of osteoporotic fractures. The positive impact on BMD of conventional HRT to prevent postmenopausal bone loss and to treat established osteoporosis has been shown by many randomized controlled trials. Regarding fracture risk prevention, some clinical and epidemiological data suggest that HRT initiated in early or late postmenopause may prevent fractures if it is administered at standard doses and continued for a long time. CONCLUSION: HRT is always the reference treatment of postmenopausal symptoms related to estrogen deficiency. [less ▲]

Detailed reference viewed: 133 (0 ULiège)
Full Text
Peer Reviewed
See detailOnce weekly alendronate produces a greater decrease in bone resorption than does daily risedronate
Hosking, D.; Adami, S.; Felsenberg, D. et al

in Journal of Bone and Mineral Research (2002, September), 17(S1), 370

Detailed reference viewed: 20 (8 ULiège)
Full Text
Peer Reviewed
See detailRapid and sustained anti-fracture efficacy of strontium ranelate in postmenopausal osteoporosis
Reginster, Jean-Yves ULiege; Sawicki, A.; Devogelaer, Jean-Pierre et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 584-5

Detailed reference viewed: 18 (0 ULiège)
Full Text
Peer Reviewed
See detailDevelopment of new immunoassays for the quantification of inflammatory related cartilage degradation
Deberg, Michelle ULiege; Christgau, Stephan; Henriksen, Dennis et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 496

Detailed reference viewed: 7 (0 ULiège)
Full Text
Peer Reviewed
See detailLumiracoxib (Prexige) is effective in the treatment of osteoarthritis of the knee: a 13-week, placebo-controlled, active-comparator, double-blind study
Tannenbaum, Hyman; Berenbaum, Francis; Reginster, Jean-Yves ULiege et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 212

Detailed reference viewed: 22 (0 ULiège)
Full Text
Peer Reviewed
See detailDo willingness to pay and time trade-off approaches suitably reflect health outcomes in hip and knee osteoarthritis?
Ethgen, Olivier ULiege; Tancredi, Annalisa; Lejeune, Eric ULiege et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 73

Detailed reference viewed: 20 (4 ULiège)
Full Text
Peer Reviewed
See detailMeta-analysis of the effects of inhaled corticosteroids on bone in asthmatic and COPD patients
Richy, Florent; Bousquet, Jean; Devogelaer, Jean-Pierre et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 464

Detailed reference viewed: 7 (0 ULiège)
Full Text
Peer Reviewed
See detailSubchondral tibial bone mineral density predicts joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis
Bruyère, Olivier ULiege; LAMBERT, Virginie ULiege; Dardenne, Charles et al

in Arthritis and Rheumatism (2002, September), 16(number 9 (suppl.)), 154

Detailed reference viewed: 7 (0 ULiège)
Full Text
Peer Reviewed
See detailClinical severity of knee osteoarthritis poorly predicts long-term radiographic outcomes
Bruyère, Olivier ULiege; Ethgen, Olivier ULiege; Lejeune, Eric ULiege et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 153

Detailed reference viewed: 19 (5 ULiège)
Full Text
Peer Reviewed
See detailBaseline measurement of urine pyridinoline and deoxypyridinoline is correlated with 3-year hip osteoarthritis progression
Bruyère, Olivier ULiege; COLLETTE, Julien ULiege; Lejeune, Eric ULiege et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 149

Detailed reference viewed: 11 (1 ULiège)
Full Text
Peer Reviewed
See detailEfficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial
Delmas, P. D.; Ensrud, K. E.; Adachi, J. D. et al

in Journal of Clinical Endocrinology and Metabolism (2002), 87(8), 3609-3617

The Multiple Outcomes of Raloxifene Evaluation trial studied 7705 postmenopausal women with osteoporosis randomized to placebo, or raloxifene 60 or 120 mg/d [JAMA 282(1999):6371. This report assesses the ... [more ▼]

The Multiple Outcomes of Raloxifene Evaluation trial studied 7705 postmenopausal women with osteoporosis randomized to placebo, or raloxifene 60 or 120 mg/d [JAMA 282(1999):6371. This report assesses the efficacy of raloxifene on the long-term cumulative incidence new vertebral fractures through 4 yr. New vertebral fractures was assessed from radiographs taken at baseline, yr 2-4. The primary analysis was the cumulative incidence of new vertebral fractures through 4 yr. A posthoc analysis compared the vertebral fracture risk in yr 4 alone with that observed in the first 3 yr. The 4-yr cumulative relative risks (RR) for one or more new vertebral fractures were 0.64 [95% confidence interval (CI) 0.53, 0.761 with raloxifene 60 mg/d and 0.57 (95% CI 0.48, 0.69) with raloxifene 120 mg/d. In yr 4 alone, raloxifene 60 mg/d reduced the new vertebral fracture risk by 39% [RR 0.61 (95% CI 0.43,0.88)], which was not found to be significantly different from the RR observed in the first 3 yr in both raloxifene groups, irrespective of prevalent fracture status. The nonvertebral fracture risk was not significantly reduced [RR 0.93 (95% CI 0.81, 1.06)]. The safety profile after 4 yr was similar to that observed after 3 yr. Raloxifene 60 and 120 mg/d through 4 yr decreased the cumulative risk of new vertebral fractures in postmenopausal women with osteoporosis. The decreased vertebral fracture risk in yr 4 alone was not different from that observed in the first 3 yr. [less ▲]

Detailed reference viewed: 18 (0 ULiège)
Full Text
Peer Reviewed
See detailRisk indices and osteoporosis screening: Scope and limits
Ben Sedrine, Wafa ULiege; Reginster, Jean-Yves ULiege

in Mayo Clinic Proceedings (2002), 77(7), 622-623

Detailed reference viewed: 9 (2 ULiège)
Full Text
Peer Reviewed
See detailDevelopment and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry
Sedrine, W. B.; Chevallier, T.; Zegels, Brigitte ULiege et al

in Gynecological Endocrinology : The Official Journal of the International Society of Gynecological Endocrinology (2002), 16(3), 245-250

A simple questionnaire would be useful to identify individuals most in need of bone mineral density (BMD) testing. We designed a new predictive model and risk assessment instrument based on an extensive ... [more ▼]

A simple questionnaire would be useful to identify individuals most in need of bone mineral density (BMD) testing. We designed a new predictive model and risk assessment instrument based on an extensive review of the literature evaluating risk factors for osteoporosis, and tested its performance in a large cohort of postmenopausal women in whom BMD was measured by dual x-ray absorptiometry. In total, 1303 postmenopausal women from an outpatient osteoporosis clinic participated in this study. The Osteoporosis Index of Risk (OSIRIS) is based on four variables: age, body weight, current hormone replacement therapy use and history of previous low impact fracture. The sensitivity and specificity for an OSIRIS value of +1 were respectively 78.5% and 51.4%. The AUC under the ROC curve of OSIRIS was 0.71. Three categories were arbitrarily created using OSIRIS, with cutoff of +1 and -3. The low risk category (OSIRIS > +1) represented 41% of all women; only 7% of the women in this category had osteoporosis. The prevalence of osteoporosis was very high (66%) among the group at high risk (OSIRIS < -3 representing 15% of all women). The prevalence of osteoporosis was 39% in the intermediate risk group (-3 < OSIRIS < +1, 44% of all women). In conclusion, OSIRIS is a simple index based on four easy-to-collect variables from postmenopausal women, it shows a high degree of accuracy, and performed well for classifying the degree of risk of osteoporosis in western European women of Caucasian lineage. Based on this instrument it is possible to propose a strategy that would initiate treatment in women with very high risk, postpone BMD measurement in women with low risk and limit BMD measurement to women with intermediate risk of osteoporosis, this would spare more than 55% of the densitometry bill compared with a mass screening scenario. [less ▲]

Detailed reference viewed: 21 (2 ULiège)